O	0	7	Fifteen
O	7	8	-
O	8	12	year
O	13	20	results
O	21	23	of
O	24	25	a
O	26	36	randomized
O	37	42	phase
O	43	46	III
O	47	52	trial
O	53	55	of
B-intervention	56	67	fenretinide
O	68	70	to
O	71	78	prevent
O	79	85	second
O	86	92	breast
O	93	99	cancer
O	99	100	.

O	101	104	The
O	105	114	synthetic
O	115	123	retinoid
O	124	135	fenretinide
O	136	148	administered
O	149	152	for
O	153	154	5
O	155	160	years
O	161	164	for
O	165	175	prevention
O	176	178	of
O	179	185	second
O	186	192	breast
O	193	199	cancer
O	200	206	showed
O	207	209	no
O	210	220	difference
O	221	226	after
O	227	228	a
O	229	235	median
O	236	238	of
O	239	240	8
O	241	246	years
O	246	247	,
O	248	251	but
O	252	253	a
O	254	262	possible
O	263	272	reduction
O	273	275	in
O	276	289	premenopausal
O	290	295	women
O	295	296	.

O	297	299	We
O	300	309	conducted
O	310	311	a
O	312	316	long
O	316	317	-
O	317	321	term
O	322	330	analysis
O	331	333	in
O	334	335	a
O	336	344	subgroup
O	345	347	of
O	348	353	women
O	354	357	who
O	358	362	were
O	363	372	regularly
O	373	381	followed
O	382	384	up
O	385	387	in
O	388	389	a
O	390	396	single
O	397	403	center
O	403	404	.

O	405	407	We
O	408	416	analyzed
O	417	421	data
O	422	427	after
O	428	429	a
O	430	436	median
O	437	443	follow
O	443	444	-
O	444	446	up
O	447	449	of
O	450	452	14
O	452	453	.
O	453	454	6
O	455	460	years
O	461	462	(
O	462	464	IQ
O	465	470	range
O	470	471	,
O	472	474	12
O	474	475	.
O	475	476	3
O	476	477	-
O	477	479	16
O	479	480	.
O	480	481	3
O	482	487	years
O	487	488	)
O	489	493	from
B-total-participants	494	498	1739
O	499	504	women
B-age	505	509	aged
I-age	510	512	30
I-age	512	513	-
I-age	513	515	70
O	516	517	(
B-intervention-participants	517	520	872
O	521	523	in
O	524	527	the
O	528	539	fenretinide
O	540	543	arm
O	544	547	and
B-control-participants	548	551	867
O	552	554	in
O	555	558	the
B-control	559	570	observation
O	571	574	arm
O	574	575	)
O	575	576	,
O	577	589	representing
O	590	592	60
O	592	593	%
O	594	596	of
O	597	600	the
O	601	608	initial
O	609	615	cohort
O	616	618	of
O	619	623	2867
O	624	629	women
O	629	630	.

O	631	634	The
O	635	639	main
O	640	648	efficacy
O	649	657	endpoint
O	658	661	was
B-outcome-Measure	662	668	second
I-outcome-Measure	669	676	primary
I-outcome-Measure	677	683	breast
I-outcome-Measure	684	690	cancer
I-outcome-Measure	691	692	(
I-outcome-Measure	692	705	contralateral
I-outcome-Measure	706	708	or
I-outcome-Measure	709	720	ipsilateral
I-outcome-Measure	720	721	)
O	721	722	.

O	723	726	The
B-outcome	727	733	number
I-outcome	734	736	of
I-outcome	737	743	second
I-outcome	744	750	breast
I-outcome	751	758	cancers
O	759	762	was
B-iv-bin-abs	763	766	168
O	767	769	in
O	770	773	the
O	774	785	fenretinide
O	786	789	arm
O	790	793	and
B-cv-bin-abs	794	797	190
O	798	800	in
O	801	804	the
O	805	812	control
O	813	816	arm
O	817	818	(
O	818	824	hazard
O	825	830	ratio
O	831	832	=
O	833	834	0
O	834	835	.
O	835	837	83
O	837	838	,
O	839	841	95
O	841	842	%
O	843	845	CI
O	845	846	,
O	847	848	0
O	848	849	.
O	849	851	67
O	851	852	-
O	852	853	1
O	853	854	.
O	854	856	03
O	856	857	)
O	857	858	.

O	859	864	There
O	865	869	were
B-iv-bin-abs	870	872	83
B-outcome	873	879	events
O	880	882	in
O	883	886	the
O	887	898	fenretinide
O	899	902	arm
O	903	906	and
B-cv-bin-abs	907	910	126
O	911	913	in
O	914	917	the
O	918	929	observation
O	930	933	arm
O	934	936	in
O	937	950	premenopausal
O	951	956	women
O	957	958	(
O	958	960	HR
O	961	962	=
O	963	964	0
O	964	965	.
O	965	967	62
O	967	968	,
O	969	971	95
O	971	972	%
O	973	975	CI
O	975	976	,
O	977	978	0
O	978	979	.
O	979	981	46
O	981	982	-
O	982	983	0
O	983	984	.
O	984	986	83
O	986	987	)
O	987	988	,
O	989	992	and
B-iv-bin-abs	993	995	85
O	996	999	and
B-cv-bin-abs	1000	1002	64
O	1003	1009	events
O	1010	1012	in
O	1013	1027	postmenopausal
O	1028	1033	women
O	1034	1035	(
O	1035	1037	HR
O	1038	1039	=
O	1040	1041	1
O	1041	1042	.
O	1042	1044	23
O	1044	1045	,
O	1046	1048	95
O	1048	1049	%
O	1050	1052	CI
O	1052	1053	,
O	1054	1055	0
O	1055	1056	.
O	1056	1058	63
O	1058	1059	-
O	1059	1060	2
O	1060	1061	.
O	1061	1063	40
O	1063	1064	)
O	1064	1065	.

O	1066	1069	The
O	1070	1077	younger
O	1078	1082	were
O	1083	1086	the
O	1087	1092	women
O	1092	1093	,
O	1094	1097	the
O	1098	1105	greater
O	1106	1109	was
O	1110	1113	the
O	1114	1118	risk
O	1119	1128	reduction
O	1129	1139	associated
O	1140	1144	with
O	1145	1156	fenretinide
O	1156	1157	,
O	1158	1163	which
O	1164	1172	attained
O	1173	1175	50
O	1175	1176	%
O	1177	1179	in
O	1180	1185	women
O	1186	1190	aged
O	1191	1193	40
O	1194	1199	years
O	1200	1202	or
O	1203	1210	younger
O	1211	1214	and
O	1215	1226	disappeared
O	1227	1232	after
O	1233	1236	age
O	1237	1239	55
O	1240	1241	(
O	1241	1242	P
O	1242	1243	-
O	1243	1246	age
O	1246	1247	*
O	1247	1256	treatment
O	1257	1268	interaction
O	1269	1270	=
O	1271	1272	0
O	1272	1273	.
O	1273	1276	023
O	1276	1277	)
O	1277	1278	.

O	1279	1284	There
O	1285	1288	was
O	1289	1291	no
O	1292	1302	difference
O	1303	1305	in
B-outcome	1306	1313	cancers
I-outcome	1314	1316	in
I-outcome	1317	1322	other
I-outcome	1323	1329	organs
O	1329	1330	,
B-outcome	1331	1338	distant
I-outcome	1339	1349	metastases
O	1350	1352	or
B-outcome	1353	1361	survival
O	1361	1362	.

O	1363	1374	Fenretinide
O	1375	1382	induces
O	1383	1384	a
O	1385	1396	significant
O	1397	1401	risk
O	1402	1411	reduction
O	1412	1414	of
O	1415	1421	second
O	1422	1428	breast
O	1429	1435	cancer
O	1436	1438	in
O	1439	1452	premenopausal
O	1453	1458	women
O	1458	1459	,
O	1460	1465	which
O	1466	1468	is
O	1469	1479	remarkable
O	1480	1482	at
O	1483	1490	younger
O	1491	1495	ages
O	1495	1496	,
O	1497	1500	and
O	1501	1509	persists
O	1510	1517	several
O	1518	1523	years
O	1524	1529	after
O	1530	1539	treatment
O	1540	1549	cessation
O	1549	1550	.

O	1551	1556	Since
O	1557	1564	adverse
O	1565	1571	events
O	1572	1575	are
O	1576	1583	limited
O	1583	1584	,
O	1585	1586	a
O	1587	1592	trial
O	1593	1595	in
O	1596	1601	young
O	1602	1607	women
O	1608	1610	at
O	1611	1615	high
O	1615	1616	-
O	1616	1620	risk
O	1621	1623	is
O	1624	1633	warranted
O	1633	1634	.
